
COVID-19 - July 14, 2021
Vaccibody enters license agreement with Adaptive Biotechnologies
Vaccibody has entered into an exclusive agreement with Adaptive Biotechnologies to use a broad selection of virus-specific T cell epitopes identified by Adaptive for Vaccibody to design and develop novel SARS-CoV-2 vaccines. Under the terms of the license agreement, Adaptive has provided certain selected T-cell epitopesfor exclusive use in Vaccibody’s next-generation SARS-CoV-2 vaccines. Vaccibody will […]

COVID-19 - June 30, 2021
Vaccibody to initiate a phase 1/2 vaccine trial
Vaccibody is initiating a phase 1/2, open label, dose escalation trial in healthy adult volunteers to determine safety and immunogenicity of two SARS CoV-2 virus DNA vaccine candidates. Vaccibody’s development strategy is to develop second-generation SARS CoV-2 vaccines that may respond to the emerging threats of evolving variants with reduced sensitivity to first generation vaccines […]

Biotech Business - March 31, 2021
Vaccibody explores potential listing on Nasdaq Global Markets in the US
Vaccibody has decided to change its financial reporting from NGAAP (Norwegian Generally Accepted Accounting Principles) and instead adopt IFRS (International Financial Reporting Standards) as its new accounting standard. Vaccibody has experienced a continued growing international interest in its stock, including a significant increase in its international investor base which has led to the company’s decision […]

Business Award - November 27, 2020
Agnete Fredriksen receives the Research Council of Norway’s innovation award
The Research Council has announced that the innovation award goes to founder and scientific director Agnete Fredriksen in Vaccibody. The innovation award will honor research-based innovation. Anne Kjersti Fahlvik, Area Director for Business Development and Innovation at the Research Council, justifies the award with “Vaccibody is a unique example of how the combination of talent, […]

Agreement - October 1, 2020
Vaccibody enters agreement with Genentech and accelerates R&D programs
Vaccibody has announced that it has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development […]

Clinical Trials - August 28, 2020
Vaccibody finalizes patient enrolment in Phase I/IIa trial
Vaccibody has reached the enrolment target of 50 patients and has finalized recruitment of patients to all study arms of its ongoing VB N-01 phase I/IIa clinical trial of the personalized VB10.NEO neoantigen cancer vaccine. “VB10.NEO is a groundbreaking approach to personalized cancer treatments and has a large commercial potential. We are thus very excited […]